Skip to main content
Erschienen in: Surgical Endoscopy 3/2011

01.03.2011 | Letter

Minimally invasive esophagectomy

verfasst von: Theodore Liakakos

Erschienen in: Surgical Endoscopy | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Excerpt

The current standard of care in the surgical treatment of early-stage esophageal cancer is complete resection of the primary tumor and regional lymph nodes (R0 resection). However, this classic open esophagectomy may be associated with increased postoperative morbidity and mortality. How can postoperative complications be reduced and quality of life improved with oncologic outcomes equal to those for open surgery? …
Literatur
1.
Zurück zum Zitat Cadière GB, Dapri G, Himpens J, Fodderie L, Rajan A (2010) Ivor Lewis esophagectomy with manual esogastric anastomosis by thoracoscopy in prone position and laparoscopy. Surg Endosc 24:1482–1485PubMedCrossRef Cadière GB, Dapri G, Himpens J, Fodderie L, Rajan A (2010) Ivor Lewis esophagectomy with manual esogastric anastomosis by thoracoscopy in prone position and laparoscopy. Surg Endosc 24:1482–1485PubMedCrossRef
2.
Zurück zum Zitat Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22:1553–1555PubMedCrossRef Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22:1553–1555PubMedCrossRef
3.
Zurück zum Zitat Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22:1402–1404PubMedCrossRef Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22:1402–1404PubMedCrossRef
4.
Zurück zum Zitat Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249:695–696PubMedCrossRef Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249:695–696PubMedCrossRef
5.
Zurück zum Zitat Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22:1405–1406PubMedCrossRef Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22:1405–1406PubMedCrossRef
6.
Zurück zum Zitat Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10:473–476PubMedCrossRef Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10:473–476PubMedCrossRef
7.
Zurück zum Zitat Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality-of-life improvement and challenges for improving long-term outcomes. Ann Surg 250:349–350PubMedCrossRef Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality-of-life improvement and challenges for improving long-term outcomes. Ann Surg 250:349–350PubMedCrossRef
8.
Zurück zum Zitat Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRef Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRef
9.
10.
Zurück zum Zitat Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9:1413–1416PubMedCrossRef Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 9:1413–1416PubMedCrossRef
11.
Zurück zum Zitat Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249:1067–1068PubMedCrossRef Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249:1067–1068PubMedCrossRef
12.
Zurück zum Zitat Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16:1771–1782PubMedCrossRef Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16:1771–1782PubMedCrossRef
13.
Zurück zum Zitat Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9:227–229PubMedCrossRef Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9:227–229PubMedCrossRef
14.
Zurück zum Zitat Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9:389–392PubMedCrossRef Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9:389–392PubMedCrossRef
15.
Zurück zum Zitat Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360:1362 (author reply 1363)PubMedCrossRef Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360:1362 (author reply 1363)PubMedCrossRef
16.
Zurück zum Zitat Roukos DH, Lykoudis E, Liakakos T (2009) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26:4360–4361CrossRef Roukos DH, Lykoudis E, Liakakos T (2009) Genomics and challenges toward personalized breast cancer local control. J Clin Oncol 26:4360–4361CrossRef
17.
Zurück zum Zitat Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16:774–775PubMedCrossRef Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16:774–775PubMedCrossRef
18.
Zurück zum Zitat Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17PubMedCrossRef Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17PubMedCrossRef
19.
Zurück zum Zitat Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16:795–798PubMedCrossRef Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16:795–798PubMedCrossRef
20.
Zurück zum Zitat Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681PubMedCrossRef Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16:2678–2681PubMedCrossRef
21.
Zurück zum Zitat Roukos DH (2010) Bionetworks-based personalized medicine versus comparative: effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10:247–250PubMedCrossRef Roukos DH (2010) Bionetworks-based personalized medicine versus comparative: effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10:247–250PubMedCrossRef
22.
Zurück zum Zitat Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28:e279–e280PubMedCrossRef Roukos DH (2010) Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J Clin Oncol 28:e279–e280PubMedCrossRef
23.
Zurück zum Zitat Roukos DH (2009) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11:283–287CrossRef Roukos DH (2009) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11:283–287CrossRef
24.
Zurück zum Zitat Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10:123–128PubMedCrossRef Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10:123–128PubMedCrossRef
25.
Zurück zum Zitat Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10:33–48PubMedCrossRef Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 10:33–48PubMedCrossRef
26.
Zurück zum Zitat Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545PubMedCrossRef Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10(5):541–545PubMedCrossRef
27.
Zurück zum Zitat Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773PubMedCrossRef Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773PubMedCrossRef
28.
Zurück zum Zitat Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338PubMedCrossRef Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338PubMedCrossRef
29.
Zurück zum Zitat Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6PubMedCrossRef Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene-environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6PubMedCrossRef
Metadaten
Titel
Minimally invasive esophagectomy
verfasst von
Theodore Liakakos
Publikationsdatum
01.03.2011
Verlag
Springer-Verlag
Erschienen in
Surgical Endoscopy / Ausgabe 3/2011
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-010-1241-5

Weitere Artikel der Ausgabe 3/2011

Surgical Endoscopy 3/2011 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.